Cytophage Technologies Ltd.
CYTO.V
TSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.66M | 2.81M | 3.25M | 3.45M | 3.41M |
| Depreciation & Amortization | 565.30K | 561.60K | 516.20K | 520.60K | 475.20K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.27M | 3.39M | 3.78M | 3.99M | 3.91M |
| Operating Income | -3.27M | -3.39M | -3.78M | -3.99M | -3.91M |
| Income Before Tax | -3.31M | -3.41M | -5.78M | -5.84M | -5.77M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.31 | -3.41 | -5.78 | -5.84 | -5.77 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.31M | -3.41M | -5.78M | -5.84M | -5.77M |
| EBIT | -3.27M | -3.39M | -3.78M | -3.99M | -3.91M |
| EBITDA | -2.89M | -2.97M | -3.36M | -3.59M | -3.51M |
| EPS Basic | -0.06 | -0.06 | -0.11 | -0.12 | -0.12 |
| Normalized Basic EPS | -0.04 | -0.04 | -0.04 | -0.05 | -0.05 |
| EPS Diluted | -0.06 | -0.06 | -0.12 | -0.12 | -0.12 |
| Normalized Diluted EPS | -0.04 | -0.04 | -0.04 | -0.05 | -0.05 |
| Average Basic Shares Outstanding | 217.37M | 215.47M | 211.32M | 200.19M | 189.02M |
| Average Diluted Shares Outstanding | 217.37M | 215.47M | 211.32M | 200.19M | 189.02M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |